{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Patients receive recombinant EphB4-HSA fusion protein intravenously (IV) over 60 minutes on days 1 and 15. Patients also receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9, or decitabine IV on days 1-5. Administration of recombinant EphB4-HSA fusion protein occurs before or after the HMA (not concurrently). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given IV or SC\n\nDecitabine: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nRecombinant EphB4-HSA Fusion Protein: Given IV","id":"OG000","title":"Treatment (sEphB4-HSA, Azacitidine, Decitabine)"}],"populationDescription":"Not performed, study terminated early.","reportingStatus":"POSTED","timeFrame":"At Baseline, then up to 3 years.","title":"Change in the Percent of Bone Marrow and Peripheral Blood Blasts Expressing EphB4 Assessed by Flow Cytometry","type":"OTHER_PRE_SPECIFIED"}